| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 9 | 2025 | 139 | 5.720 |
Why?
|
| Leukemia, Myeloid, Acute | 17 | 2024 | 815 | 3.870 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2025 | 923 | 2.300 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2024 | 407 | 2.150 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2024 | 368 | 1.950 |
Why?
|
| Disease Management | 8 | 2025 | 340 | 1.760 |
Why?
|
| Sulfonamides | 4 | 2024 | 328 | 1.580 |
Why?
|
| Aminopyridines | 2 | 2023 | 45 | 1.510 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2023 | 24 | 1.490 |
Why?
|
| Triazines | 2 | 2023 | 55 | 1.490 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2024 | 97 | 1.110 |
Why?
|
| Anemia | 2 | 2024 | 133 | 1.030 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2368 | 0.940 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2024 | 462 | 0.900 |
Why?
|
| CD47 Antigen | 1 | 2024 | 22 | 0.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2556 | 0.870 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 57 | 0.860 |
Why?
|
| Aniline Compounds | 1 | 2023 | 61 | 0.850 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 56 | 0.840 |
Why?
|
| Pyrazines | 1 | 2023 | 92 | 0.830 |
Why?
|
| Air Pollutants | 1 | 2024 | 97 | 0.820 |
Why?
|
| Mutation | 11 | 2024 | 4204 | 0.810 |
Why?
|
| Humans | 58 | 2025 | 92337 | 0.770 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 109 | 0.740 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2024 | 429 | 0.730 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2021 | 16 | 0.720 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2021 | 22 | 0.720 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 14 | 0.710 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 183 | 0.700 |
Why?
|
| Disease Susceptibility | 4 | 2024 | 207 | 0.690 |
Why?
|
| Pyrrolidines | 1 | 2020 | 60 | 0.680 |
Why?
|
| Benzamides | 1 | 2020 | 239 | 0.650 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 74 | 0.640 |
Why?
|
| Blast Crisis | 3 | 2024 | 37 | 0.630 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 119 | 0.630 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 245 | 0.630 |
Why?
|
| Pyrimidines | 1 | 2020 | 378 | 0.580 |
Why?
|
| Treatment Outcome | 10 | 2024 | 8740 | 0.550 |
Why?
|
| Middle Aged | 20 | 2024 | 27030 | 0.490 |
Why?
|
| Primary Myelofibrosis | 2 | 2024 | 67 | 0.440 |
Why?
|
| Disease Progression | 3 | 2024 | 1503 | 0.420 |
Why?
|
| Male | 20 | 2024 | 43925 | 0.410 |
Why?
|
| Antibodies, Bispecific | 3 | 2021 | 31 | 0.390 |
Why?
|
| Aged | 17 | 2024 | 19943 | 0.390 |
Why?
|
| Azacitidine | 2 | 2024 | 148 | 0.390 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6916 | 0.380 |
Why?
|
| Retreatment | 2 | 2022 | 107 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 598 | 0.360 |
Why?
|
| Risk Factors | 5 | 2024 | 5704 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 622 | 0.360 |
Why?
|
| Adult | 17 | 2024 | 27532 | 0.340 |
Why?
|
| Enzyme Inhibitors | 2 | 2023 | 652 | 0.340 |
Why?
|
| Female | 17 | 2024 | 47893 | 0.320 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 2394 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 291 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1398 | 0.280 |
Why?
|
| Hemoglobins | 2 | 2024 | 190 | 0.270 |
Why?
|
| Prognosis | 6 | 2024 | 3872 | 0.260 |
Why?
|
| Remission Induction | 3 | 2024 | 763 | 0.260 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 130 | 0.260 |
Why?
|
| Philadelphia Chromosome | 2 | 2024 | 44 | 0.250 |
Why?
|
| Prospective Studies | 3 | 2024 | 4468 | 0.250 |
Why?
|
| Young Adult | 9 | 2024 | 6624 | 0.250 |
Why?
|
| Mastocytosis, Systemic | 1 | 2024 | 12 | 0.230 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2024 | 79 | 0.210 |
Why?
|
| Air Pollution | 1 | 2024 | 93 | 0.210 |
Why?
|
| Janus Kinase 2 | 1 | 2023 | 59 | 0.200 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1592 | 0.200 |
Why?
|
| Adolescent | 7 | 2024 | 9504 | 0.190 |
Why?
|
| Cytogenetics | 1 | 2021 | 28 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 276 | 0.190 |
Why?
|
| Leukemia | 1 | 2024 | 321 | 0.190 |
Why?
|
| Immunocompetence | 1 | 2021 | 27 | 0.180 |
Why?
|
| Castleman Disease | 1 | 2021 | 14 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2021 | 110 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 611 | 0.180 |
Why?
|
| Uridine | 1 | 2021 | 58 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 44 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2394 | 0.180 |
Why?
|
| Janus Kinases | 1 | 2020 | 23 | 0.180 |
Why?
|
| Clonal Evolution | 1 | 2020 | 16 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 57 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 262 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 366 | 0.170 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 85 | 0.170 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 383 | 0.170 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 117 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 137 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2020 | 235 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 61 | 0.160 |
Why?
|
| Retrospective Studies | 9 | 2024 | 9703 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 624 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 411 | 0.160 |
Why?
|
| Uncertainty | 1 | 2019 | 77 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 102 | 0.160 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2018 | 16 | 0.150 |
Why?
|
| Exercise | 1 | 2022 | 335 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 390 | 0.150 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 52 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 291 | 0.150 |
Why?
|
| Environment | 1 | 2020 | 229 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 274 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 215 | 0.150 |
Why?
|
| Genomics | 2 | 2020 | 806 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 444 | 0.140 |
Why?
|
| Neoplasms | 2 | 2023 | 3117 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1180 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 295 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 400 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 909 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2019 | 353 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1733 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 456 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 520 | 0.130 |
Why?
|
| Internal Medicine | 1 | 2019 | 364 | 0.120 |
Why?
|
| Age Factors | 1 | 2020 | 1905 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1150 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1576 | 0.120 |
Why?
|
| HIV Infections | 1 | 2024 | 895 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 2035 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2020 | 1081 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1850 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2023 | 3508 | 0.110 |
Why?
|
| Sweet Syndrome | 1 | 2013 | 6 | 0.100 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2012 | 3 | 0.100 |
Why?
|
| Histone Deacetylase 2 | 1 | 2012 | 8 | 0.100 |
Why?
|
| Allografts | 2 | 2024 | 197 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 158 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 1015 | 0.090 |
Why?
|
| Histones | 1 | 2012 | 351 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 355 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 561 | 0.070 |
Why?
|
| Animals | 3 | 2023 | 28003 | 0.070 |
Why?
|
| Fever | 2 | 2021 | 130 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 754 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2022 | 806 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2669 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 128 | 0.060 |
Why?
|
| Blood Substitutes | 1 | 2024 | 8 | 0.060 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2024 | 13 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2012 | 1684 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.050 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2024 | 23 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 134 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 328 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 36 | 0.050 |
Why?
|
| Milk | 1 | 2023 | 55 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2024 | 168 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 151 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 249 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2023 | 56 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2024 | 69 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 43 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 109 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 236 | 0.050 |
Why?
|
| Cytarabine | 1 | 2024 | 222 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 380 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2024 | 122 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 280 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 188 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 105 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 209 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 856 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 234 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 734 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 380 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 100 | 0.040 |
Why?
|
| Fatigue | 1 | 2021 | 177 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1927 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2024 | 393 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 199 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2020 | 115 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2024 | 677 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 150 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2022 | 201 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 239 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 285 | 0.040 |
Why?
|
| United States | 2 | 2024 | 7348 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 119 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 868 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2020 | 104 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2018 | 20 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 80 | 0.040 |
Why?
|
| Glycine | 1 | 2018 | 95 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 289 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 250 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1511 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 12110 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 324 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2369 | 0.030 |
Why?
|
| Apoptosis | 1 | 2023 | 1743 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 502 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 542 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 612 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2978 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2498 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2013 | 15 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1310 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2012 | 4 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2012 | 11 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 25 | 0.020 |
Why?
|
| Physicians | 1 | 2019 | 694 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 111 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 88 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2012 | 124 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 86 | 0.020 |
Why?
|
| Neutrophils | 1 | 2013 | 323 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2680 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 741 | 0.020 |
Why?
|
| Chromatin | 1 | 2012 | 417 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 968 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 434 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1513 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1163 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1247 | 0.020 |
Why?
|